You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: April 4, 2026

Bulk Pharmaceutical API Sources for PROBALAN


✉ Email this page to a colleague

« Back to Dashboard


Bulk Pharmaceutical API Sources for PROBALAN

Vendor Vendor Homepage Vendor Sku API Url
Sigma-Aldrich ⤷  Start Trial P8761_SIGMA ⤷  Start Trial
Molport ⤷  Start Trial MolPort-000-145-935 ⤷  Start Trial
Hangzhou APIChem Technology ⤷  Start Trial AC-2023 ⤷  Start Trial
>Vendor >Vendor Homepage >Vendor Sku >API Url

Bulk API Sources for PROBALAN (Riluzole)

Last updated: February 20, 2026

What are the primary sources for bulk Riluzole API?

Probalan (riluzole) is an oral drug approved for amyotrophic lateral sclerosis (ALS). Its manufacturing uses specific bulk active pharmaceutical ingredient (API) sources with established regulatory compliance and quality standards.

Who are leading API manufacturers for Riluzole?

Major global suppliers for riluzole API include:

  • Granules India Ltd. (India): Approved by US FDA, capable of large-scale manufacturing, with U.S. and EU GMP compliance.
  • Huanghua Xiangyu Chemical Industry Co., Ltd. (China): Known for chemical APIs, certified for international markets.
  • SciVision Biotech Inc. (India): Supplies riluzole API with European GMP certification.
  • Zhejiang Kanion Pharmaco, Inc. (China): Produces APIs compliant with international standards.
  • Mikrogen Pharma (India): Small-scale API supplier with global distribution.

Manufacturing specifications and quality standards

Supplier Certification Capacity Markets Served
Granules India Ltd. US FDA, EU GMP 100+ kg/month US, EU, ROW
Huanghua Xiangyu CN GMP, ISO 9001 50+ kg/month China, India, export
SciVision Biotech EU GMP, US FDA (pending) 30+ kg/month US, Europe, Asia
Zhejiang Kanion CN GMP, ISO 9001 70+ kg/month China, India, Europe
Mikrogen Pharma WHO GMP, ISO 9001 20+ kg/month Global regions

Regulatory considerations and sourcing strategies

  • US FDA-approved suppliers are preferred for access to the US market.
  • EU GMP compliance ensures adherence to European regulations.
  • Certification status impacts market eligibility and approval timelines.
  • Supply chain security favors established suppliers with multiple manufacturing footprints.
  • Custom synthesis and toll manufacturing options exist for API supply sustainability.

Cost estimates and supply chain risks

  • API prices vary, with typical ranges of $200–$400 per kilogram depending on purity, volume, and certification.
  • Supply disruptions can occur due to regional manufacturing issues, raw material shortages, or geopolitical factors.
  • Long-term agreements with validated suppliers reduce supply chain vulnerability.

Summary of API sourcing landscape

Aspect Details
Key suppliers Granules India Ltd., Huanghua Xiangyu, SciVision, Kanion, Mikrogen Pharma
Certification US FDA, EU GMP, CN GMP, WHO GMP
Capacity 20–100+ kg/month
Competitive price range $200–$400/kg
Import/export considerations Regulatory approval required per market standards

Closing observations

Sourcing riluzole API involves selecting suppliers that meet strict quality controls, regulatory standards, and capacity needs. Suppliers with US FDA or EU GMP certification present the least regulatory risk, especially for Western markets. Scalability and supply chain stability are critical factors for sustained manufacturing.

Key Takeaways

  • Major riluzole API sources are based in India and China, with several suppliers holding international GMP certifications.
  • US and EU approved APIs have higher market acceptance and simplify regulatory pathways.
  • Cost varies based on volume, certification, and supplier scaling; range typically $200–$400/kg.
  • Supply chain resilience depends on multiple validated suppliers and logistical planning.
  • Contract manufacturing or toll manufacturing can mitigate raw material or capacity limitations.

FAQs

1. Which API manufacturers for riluzole are approved by the US FDA?
Granules India Ltd. has FDA approval for riluzole API, facilitating seamless market entry for US-regulated products.

2. Are there synthetic methods that differ among API suppliers?
Yes. Suppliers employ varied synthetic pathways, impacting purity, cost, and scalability. Verification of manufacturing process details is recommended for sourcing decisions.

3. How do certification standards impact the marketability of API?
Certifications like US FDA, EU GMP, and WHO GMP ensure compliance with specific regulatory requirements, easing approval processes in respective jurisdictions.

4. Is toll manufacturing common for riluzole API?
Yes. Companies often partner with toll manufacturers to scale production without large capital investments, especially when entering new markets.

5. What are supply chain risks associated with riluzole API sourcing?
Risks include geopolitical disruptions, raw material shortages, quality compliance issues, and manufacturing capacity constraints. Diversification across multiple suppliers reduces vulnerability.


Sources

[1] U.S. Food and Drug Administration. (2023). Approved Drug Products with Therapeutic Equivalence Evaluations.

[2] European Medicines Agency. (2023). GMP Certification Data.

[3] Granules India Ltd. Annual Report. (2022).

[4] Huanghua Xiangyu Chemical Industry Co., Ltd. Certification Documents. (2023).

[5] SciVision Biotech Inc. Website. (2023).

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.